SE0301654D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0301654D0
SE0301654D0 SE0301654A SE0301654A SE0301654D0 SE 0301654 D0 SE0301654 D0 SE 0301654D0 SE 0301654 A SE0301654 A SE 0301654A SE 0301654 A SE0301654 A SE 0301654A SE 0301654 D0 SE0301654 D0 SE 0301654D0
Authority
SE
Sweden
Prior art keywords
novel compounds
pyridazine
therapy
triazine compounds
compounds
Prior art date
Application number
SE0301654A
Other languages
English (en)
Swedish (sv)
Inventor
David Cheshire
Nicholas Kindon
Michael Stocks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301654A priority Critical patent/SE0301654D0/xx
Publication of SE0301654D0 publication Critical patent/SE0301654D0/xx
Priority to TW093114511A priority patent/TW200509935A/zh
Priority to JP2006508571A priority patent/JP2006526619A/ja
Priority to PCT/SE2004/000851 priority patent/WO2004108690A1/en
Priority to US10/559,202 priority patent/US20060189613A1/en
Priority to EP04735834A priority patent/EP1633723A1/en
Priority to UY28345A priority patent/UY28345A1/es
Priority to ARP040101942A priority patent/AR044613A1/es
Priority to SA04250149A priority patent/SA04250149A/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0301654A 2003-06-05 2003-06-05 Novel compounds SE0301654D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds
TW093114511A TW200509935A (en) 2003-06-05 2004-05-21 Novel compounds
JP2006508571A JP2006526619A (ja) 2003-06-05 2004-06-02 ケモカイン受容体活性(ccr4)を調節するスルホンアミド化合物
PCT/SE2004/000851 WO2004108690A1 (en) 2003-06-05 2004-06-02 Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
US10/559,202 US20060189613A1 (en) 2003-06-05 2004-06-02 Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
EP04735834A EP1633723A1 (en) 2003-06-05 2004-06-02 Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
UY28345A UY28345A1 (es) 2003-06-05 2004-06-03 Compuestos novedosos
ARP040101942A AR044613A1 (es) 2003-06-05 2004-06-04 Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4)
SA04250149A SA04250149A (ar) 2003-06-05 2004-06-05 مركبات جديدة

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds

Publications (1)

Publication Number Publication Date
SE0301654D0 true SE0301654D0 (sv) 2003-06-05

Family

ID=29212393

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds

Country Status (9)

Country Link
US (1) US20060189613A1 (xx)
EP (1) EP1633723A1 (xx)
JP (1) JP2006526619A (xx)
AR (1) AR044613A1 (xx)
SA (1) SA04250149A (xx)
SE (1) SE0301654D0 (xx)
TW (1) TW200509935A (xx)
UY (1) UY28345A1 (xx)
WO (1) WO2004108690A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
AU2014267360B2 (en) * 2013-05-14 2018-07-05 Active Biotech Ab N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
IL274444B1 (en) 2017-11-06 2024-02-01 Rapt Therapeutics Inc Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
TW202039512A (zh) 2018-12-06 2020-11-01 日商第一三共股份有限公司 環烷-1,3-二胺化合物
US20220127247A1 (en) * 2019-02-06 2022-04-28 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
DE60140263D1 (de) * 2000-09-25 2009-12-03 Actelion Pharmaceuticals Ltd Arylalkanen-sulfonamiden mit endothelin-antagonistischer aktivität
WO2002030357A2 (en) * 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
JP2006526619A (ja) 2006-11-24
EP1633723A1 (en) 2006-03-15
TW200509935A (en) 2005-03-16
UY28345A1 (es) 2005-01-31
AR044613A1 (es) 2005-09-21
US20060189613A1 (en) 2006-08-24
SA04250149A (ar) 2005-12-03
WO2004108690A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE461217T1 (de) Glp-1-verbindungen
AU302959S (en) Toothbrush
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
NL1025068A1 (nl) Pyrrolopyrimidinederivaten.
MX267068B (es) Derivados simetricos de triazina.
MXPA03007140A (es) Derivados de carbolina.
DE602005011780D1 (de) Triazinderivate mit carbamatfunktion
DK1585737T3 (da) Uraciler med herbicid virkning
WO2007120333A3 (en) Tetracyclic kinase inhibitors
SE0301654D0 (sv) Novel compounds
SE0301650D0 (sv) Novel compounds
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
RS51138B (sr) S-mirtazapin za lečenje nastupa vreline (valunga)
NO20054064L (no) Slipemaskin.
DK1713438T3 (da) Medicinsk sæbe
WO2007076320A8 (en) Compounds
UY3450Q (es) Botella
DE50309381D1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
PL376130A1 (en) Controlled releases system containing temozolomide